Description
ALBACYTE C3 BLOOD REAGENTS
First action · last action
2019-10-01 · 2023-04-25
Transactions
6
First transaction's obligation
$22,107
Base + all options value (sum of deltas)
$64,472
Extent competed
FULL AND OPEN COMPETITION
Other than full & open authority
—
Set-aside
—
Offers received
1
SDVOSB flag on record
No
Parent IDV
V797P2050D
NAICS
325413 · IN-VITRO DIAGNOSTIC SUBSTANCE MANUFACTURING
Modification chain · 6 transactions
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2019-10-01+$22,107= $22,107
- Mod P000012020-10-01+$22,107= $44,214
- Mod P000022021-10-01+$21,924= $66,138
- Mod P000032022-01-24+$0= $66,138
- Mod P000062022-12-20-$1,218= $64,921
- Mod P000082023-04-25-$449= $64,472
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2019-10-01 | +$22,107 | $22,107 | ALBACYTE C3 BLOOD REAGENTS |
| Mod P00001· EXERCISE AN OPTION | 2020-10-01 | +$22,107 | $44,214 | ALBACYTE C3 BLOOD REAGENTS |
| Mod P00002· EXERCISE AN OPTION | 2021-10-01 | +$21,924 | $66,138 | ALBACYTE C3 BLOOD REAGENTS |
| Mod P00003· OTHER ADMINISTRATIVE ACTION | 2022-01-24 | +$0 | $66,138 | ALBACYTE C3 BLOOD REAGENTS |
| Mod P00006· FUNDING ONLY ACTION | 2022-12-20 | −$1,218 | $64,921 | ALBACYTE C3 BLOOD REAGENTS |
| Mod P00008· FUNDING ONLY ACTION | 2023-04-25 | −$449 | $64,472 | ALBACYTE C3 BLOOD REAGENTS |
Related awards · 11
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI V6KNKL6BDHL7)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| 36C25526N0306 | 255-NETWORK CONTRACT OFFICE 15 (36C255) · 6550 · IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS | $40,949 | FY2026 |
| 36C25926N0280 | NETWORK CONTRACT OFFICE 19 (36C259) · 6550 · IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS | $64,078 | FY2026 |
| 36C25726N0176 | 257-NETWORK CONTRACT OFFICE 17 (36C257) · 6505 · DRUGS AND BIOLOGICALS | $7,634 | FY2026 |
| 36C25726N0224 | 257-NETWORK CONTRACT OFFICE 17 (36C257) · 6550 · IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS | $16,514 | FY2026 |
| 36C25626N0214 | 256-NETWORK CONTRACT OFFICE 16 (36C256) · 6550 · IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS | $23,127 | FY2026 |
| 36C25026N0043 | 250-NETWORK CONTRACT OFFICE 10 (36C250) · 6550 · IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS | $21,884 | FY2026 |
Other recipients under 6550 from 250-NETWORK CONTRACT OFFICE 10 (36C250) (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| 36C25026N0794 | ROCHE DIAGNOSTICS CORPORATION | 250-NETWORK CONTRACT OFFICE 10 (36C250) | $200,000 | FY2026 |
| 36C25026N0788 | ROCHE DIAGNOSTICS CORPORATION | 250-NETWORK CONTRACT OFFICE 10 (36C250) | $135,282 | FY2026 |
| 36C25026N0718 | ABBOTT LABORATORIES INC. | 250-NETWORK CONTRACT OFFICE 10 (36C250) | $212,150 | FY2026 |
| 36C25026N0778 | LEICA MICROSYSTEMS INC. | 250-NETWORK CONTRACT OFFICE 10 (36C250) | $120,282 | FY2026 |
| 36C25026F0645 | GOVERNMENT SCIENTIFIC SOURCE INC | 250-NETWORK CONTRACT OFFICE 10 (36C250) | $53,963 | FY2026 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_AWD_36C25020F0072_3600_V797P2050D_3600 · retrieved 2026-09-26.